Teppo Huttunen, a Finnish statistician and founder of Eskimage, delves into the complexities of dose selection in immune-oncology. He discusses the challenges of traditional 3+3 design and advocates for the more flexible BOIN design. Teppo emphasizes the balance between safety and efficacy, exploring the crucial role statisticians play in oncology research. He also highlights the importance of industry trends, FDA guidance, and practical challenges in optimizing dose design, making this conversation essential for anyone interested in advancing oncology treatment.